Potent synergistic combination of rosuvastatin and levofloxacin against Staphylococcus aureus : in vitro and in vivo study
| Autor: | Ahmed A. Abdelaziz, Rana A Mahmoud El-Nagar, El-Barrawy Ma |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Coagulase
Male Staphylococcus aureus Virulence Factors Bacterial Toxins Levofloxacin Microbial Sensitivity Tests Pharmacology Skin infection medicine.disease_cause Applied Microbiology and Biotechnology Hemolysin Proteins Mice 03 medical and health sciences Minimum inhibitory concentration Antibiotic resistance In vivo medicine Animals Rosuvastatin Rosuvastatin Calcium 030304 developmental biology Mice Inbred BALB C 0303 health sciences 030306 microbiology business.industry nutritional and metabolic diseases Drug Resistance Microbial Drug Synergism General Medicine Staphylococcal Infections medicine.disease Anti-Bacterial Agents Disease Models Animal Drug Combinations Sphingomyelin Phosphodiesterase Biofilms Wound Infection business Biotechnology medicine.drug |
| Zdroj: | Journal of Applied Microbiology. 131:182-196 |
| ISSN: | 1365-2672 1364-5072 |
| DOI: | 10.1111/jam.14968 |
| Popis: | AIMS The present study aims to evaluate the capability of rosuvastatin to synergize with levofloxacin against Staphylococcus aureus. METHODS AND RESULTS Rosuvastatin inhibited the growth of S. aureus with minimum inhibitory concentration of 16 μg ml-1 . Additionally, it showed a bactericidal effect at 4x minimum inhibition concentration. Using a checkerboard method, a synergistic effect was recorded when rosuvastatin was combined with levofloxacin showing against S. aureus isolate 28 (S 28). Furthermore, this combination was also able to display a significant reduction in biofilm formation (92·8%) and suppress the production of coagulase and β-haemolysin, and virulence factors of S. aureus isolate 28. An animal model for wound infection was used to assess the therapeutic effect of the test combination, in vivo. It was found that the test combination reduced the bacterial burden in the infected wounds by 91·3%. Pathological and histological analyses have revealed a decline in cell infiltration in the excisional wound skin tissue after treatment with rosuvastatin and levofloxacin combination. CONCLUSIONS Rosuvastatin combined with levofloxacin can be considered as a promising solution to combat S. aureus antibiotic resistance phenomenon. SIGNIFICANCE AND IMPACT OF THE STUDY This study unveils the potential effect of rosuvastatin when used in combination with levofloxacin can be used as a topical antibacterial agent to treat S. aureus skin infections. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text